Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
USM101
- Development stage
- Preclinical
- Lead developer
- Uscare Pharm
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
USM101 is a preclinical-stage therapeutic candidate being developed by **Uscare Pharm**, a South Korean biotechnology company specializing in medical aesthetics and biomaterials. It is currently under investigation for **fat reduction** applications. Categorized within the company's 'Material Innovation' pipeline, USM101 is intended to address localized adiposity. As of 2024, the program is in non-clinical development, with specific molecular targets and chemical structures not yet publicly disclosed. The asset is part of a broader innovation strategy that distinguishes between new materials (USM series) and finished products (USP series).
Beyond the preview
Go deeper on USM101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USM101.